Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

G
Gaballah, Sameh

H Lee Moffitt Cancer Center & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Sameh Gaballah
Favorite
Gabus, Raul

Hospital Maciel
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Raul Gabus
Favorite
Gafencu, Grigore-Aristide

Oxford Molecular Diagnostic Centre, Department of Oncology, University of Oxford
1202 - T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study
Grigore-Aristide Gafencu
Favorite
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Grigore-Aristide Gafencu
Favorite
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Grigore-Aristide Gafencu
Favorite
Gaidano, Gianluca

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Gianluca Gaidano
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Gianluca Gaidano
Favorite
Gajdoš, Petr
1157 - Significance of TP53 aberrations in context of other pathogenic sequence variants in patients with chronic lymphocytic leukemia in the era of targeted therapy
Petr Gajdoš
Favorite
Galitzia, Andrea

Department of Medical Sciences and Public Health, University of Cagliari
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Andrea Galitzia
Favorite
1224 - Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.
Andrea Galitzia
Favorite
Galli, Eugenio

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Eugenio Galli
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Eugenio Galli
Favorite
1219 - The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.
Eugenio Galli
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Eugenio Galli
Favorite
Gamal, Wael

H Lee Moffitt Cancer Center & Research Institute
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Wael Gamal
Favorite
1058 - T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors
Wael Gamal
Favorite
Gamberale, Romina

IMEX-CONICET-ANM
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Romina Gamberale
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Romina Gamberale
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Romina Gamberale
Favorite
Gandhi, Anita

Bristol Myers Squibb
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
Anita Gandhi
Favorite
Gandhi, Varsha

The University of Texas MD Anderson Cancer Center
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Varsha Gandhi
Favorite
Gandini, Francesca

Vita-Salute San Raffaele University
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Francesca Gandini
Favorite
Gandra, Shravanthi R.

Merck & Co., Inc.
1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States
Shravanthi R. Gandra
Favorite
García, Alfonso

Hematology Department, Hospital Clínico Universitario of Valladolid
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Alfonso García
Favorite
García-Cosío, Mónica
1030 - Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia
Mónica García-Cosío
Favorite
García-Marco, José A.

Unidad de Citogenetica Molecular, Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
José A. García-Marco
Favorite
García De Coca, Alfonso

Department of Hematology. Hospital Clínico, Valladolid
1161 - ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Alfonso García De Coca
Favorite
Garcia, Rayna

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Rayna Garcia
Favorite
Garcia-Roves, Pablo M.

University of Barcelona
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Pablo M. Garcia-Roves
Favorite
García-Serra, Rocío

Consorcio Hospital General Universitario de Valencia
1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients
Rocío García-Serra
Favorite
garnier, Delphine
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Delphine garnier
Favorite
Gastinne, Thomas

CHU Nantes
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Thomas Gastinne
Favorite
Gat, Elodie

LYSARC
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Elodie Gat
Favorite
Gattei, Valter

Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Valter Gattei
Favorite
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Valter Gattei
Favorite
2018 - Over-Time Monitoring of CXCR4dim/CD5bright Proliferative Fraction Anticipates Relapse In Ibrutinib-Treated CLL : a reservoir for BTK mutations?
Valter Gattei
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Valter Gattei
Favorite
Gavriilidis, Georgios

CERTH
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Georgios Gavriilidis
Favorite
Gazit, Sivan
1140 - Pregnancy course of 10 women diagnosed with Chronic Lymphocytic Leukemia
Sivan Gazit
Favorite
Gener-Ricos, Georgina

MD Anderson Cancer Center
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Georgina Gener-Ricos
Favorite
Gentile, Massimo

Hematology Section, Cosenza Hospital
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Massimo Gentile
Favorite
Gercheva, Liana

Clinic of Hematology, University Hospital St Marina
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Liana Gercheva
Favorite
Gerrie, Alina S.

BC Cancer Centre for Lymphoid Cancer and The University of British Columbia
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Alina S. Gerrie
Favorite
Geyer, Mark

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Mark Geyer
Favorite
Ghia, Emanuela

Moores Cancer Center, University of California San Diego
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Emanuela Ghia
Favorite
Ghia, Paolo

Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Paolo Ghia
Favorite
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Paolo Ghia
Favorite
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Paolo Ghia
Favorite
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Paolo Ghia
Favorite
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Paolo Ghia
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Paolo Ghia
Favorite
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Paolo Ghia
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Paolo Ghia
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Paolo Ghia
Favorite
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Paolo Ghia
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Paolo Ghia
Favorite
Ghnaya, Habib
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Habib Ghnaya
Favorite
Ghosh, Nilanjan

Levine Cancer Institute, Atrium Health
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Nilanjan Ghosh
Favorite
1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
Nilanjan Ghosh
Favorite
2025 - Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of first-line ibrutinib
Nilanjan Ghosh
Favorite
2027 - Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database
Nilanjan Ghosh
Favorite
Giannarelli, Diana

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1219 - The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.
Diana Giannarelli
Favorite
Giannopoulos, Krzysztof

Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland; Hematology Department, St John's Cancer Centre, Lublin, Poland
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Krzysztof Giannopoulos
Favorite
Giertz, Annika

Center for clinical cancer studies, Karolinska University Hospital
2001 - Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Annika Giertz
Favorite
Gimeno, Eva

Department of Hematology, Hospital del Mar
1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients
Eva Gimeno
Favorite
Giordano, Mirta

IMEX-CONICET-ANM
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Mirta Giordano
Favorite
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Mirta Giordano
Favorite
1051 - Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Mirta Giordano
Favorite
Giró, Ariadna

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Ariadna Giró
Favorite
Girardi, Vincent

AbbVie Inc.
1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
Vincent Girardi
Favorite
Girschikofsky, Michael

1st Medical Department, Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz GmbH, Elisabethinen
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Michael Girschikofsky
Favorite
Gizdic, Branimir

Department of Hematology, Dubrava University Hospital
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Branimir Gizdic
Favorite
Glass, Laura

Ascentage Pharma Group Inc.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Laura Glass
Favorite
Gleeson, Mary

Sarah Cannon Research Institute, Guy’s and St Thomas’ NHS Foundation Trust
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Mary Gleeson
Favorite
Göbel, Georg

Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University
1141 - Reduced predictive value of elevated Beta-2-microglobulin plasma levels on time to first treatment in newly diagnosed CLL patients with compromised kidney function
Georg Göbel
Favorite
Goebel, Benjamin

Eli Lilly and Company
2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor
Benjamin Goebel
Favorite
Goedhart, Nienke

Amsterdam University Medical Centers
1024 - Impaired mitochondrial metabolism drives T-cell dysfunction in chronic lymphocytic leukemia
Nienke Goedhart
Favorite
Goehring, Gudrun
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Gudrun Goehring
Favorite
Goldenberg, Alec

Manhattan Hem Onc Associates
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Alec Goldenberg
Favorite
Golovina, Elena

Charles University, First Faculty of Medicine, Institute of Pathological Physiology
1015 - Coupled effect of a miR-155 deficiency and hypoxia conditions leads to the upregulation of SLC2A1 (GLUT1), SLC2A3 (GLUT3) and EGLN1 genes in the leukemic B-cells
Elena Golovina
Favorite
Gonçalves, Matheus

Universidade Federal de Sao Paulo
1227 - Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Matheus Gonçalves
Favorite
González-Puelma, Jorge

Universidad de Magallanes
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Jorge González-Puelma
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Jorge González-Puelma
Favorite
Gonzalez, Hugo
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Hugo Gonzalez
Favorite
Gopal, Ajay

Fred Hutchinson Cancer Center / University of Washington School of Medicine
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Ajay Gopal
Favorite
Gordon, Britten

The Ohio State University
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Britten Gordon
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Britten Gordon
Favorite
Gordon, Max

University of Texas MD Anderson
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Max Gordon
Favorite
Gottlieb, David

Westmead Hospital
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
David Gottlieb
Favorite
Grange, Beatrice
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Beatrice Grange
Favorite
Gregory, Gareth

Department of Hematology, School of Clinical Sciences at Monash Health, Monash University
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Gareth Gregory
Favorite
Greig, Katie

Weill Cornell Medicine
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Katie Greig
Favorite
Greil, Richard

Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Richard Greil
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Richard Greil
Favorite
Grever, Michael

The Ohio State University
1158 - A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity
Michael Grever
Favorite
Grieselhuber, Nicole

The Ohio State University Comprehensive Cancer Center, The Ohio State University
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Nicole Grieselhuber
Favorite
Grieve, Clare

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Clare Grieve
Favorite
Grigg, Andrew

Austin Hospital
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Andrew Grigg
Favorite
Griggio, Valentina

1 Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3,10126, Torino, Italy
2 Department of Molecular Biotechnology and Health Sciences, University of Torino
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Valentina Griggio
Favorite
Grohovac, Dragana

University Hospital Centre Rijeka
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Dragana Grohovac
Favorite
Grosicki, Sebastian

Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Sebastian Grosicki
Favorite
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Sebastian Grosicki
Favorite
Guerin, Annie

Analysis Group, Inc.
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Annie Guerin
Favorite
Guiducci, Cristiana
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Cristiana Guiducci
Favorite
Guieze, Romain

Service Hématologie, CHU Clermont Ferrand
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Romain Guieze
Favorite
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Romain Guieze
Favorite
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Romain Guieze
Favorite
Guillermo, Cecilia

Hematology Department, Hospital de Clínicas
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Cecilia Guillermo
Favorite
1054 - The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Cecilia Guillermo
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Cecilia Guillermo
Favorite
Gui, Renfu

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Renfu Gui
Favorite
Guo, Guangyao

Fujian Institute of Hematology, Fujian Medical University Union Hospital
1107 - Mechanisms of differential response to BTKi targeted therapy in patients with chronic lymphocytic leukemia
Guangyao Guo
Favorite
Guo, Xutao

Department of Hematology, Nanfang Hospital, Southern Medical University
1025 - Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro
Xutao Guo
Favorite
3009 - Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Xutao Guo
Favorite
Guo, Zhen
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Zhen Guo
Favorite
Gutierrez, Meghan

Lymphoma Research Foundation
1204 - Real-World Characteristics and Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Long-Term Ibrutinib: Results From the Prospective, Observational informCLL Registry
Meghan Gutierrez
Favorite
Gu, Yifan

IQVIA
2007 - Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Yifan Gu
Favorite